Liver Transplantation and Bariatric Surgery: Timing and Outcomes

Tayyab S. Diwan, Teresa C. Rice, Julie K. Heimbach, Daniel P. Schauer – 6 August 2018 – Nonalcoholic steatohepatitis (NASH) is projected to become the leading indication for liver transplantation (LT) in the next decade in the United States. Strategies to treat the underlying etiology of NASH, which is almost always obesity, are being pursued. One such strategy is the utilization of bariatric surgery (BS) in the peritransplant period. The use of BS prior to LT could prevent the progression of NASH and abrogate the need for LT.

“I Miss My Liver.” Nonmedical Sources in the History of Hepatocentrism

Riccardo Orlandi, Nicole Cianci, Pietro Invernizzi, Giancarlo Cesana, Michele Augusto Riva – 6 August 2018 – Hepatocentrism was a medical doctrine that considered the liver the center of the whole human being. It originated in ancient populations (Mesopotamic civilization) and persisted in Western countries until the seventeenth century. Hidden references to hepatocentrism may be found in artistic representations and literary works, from the myth of Prometheus in the Greco‐Roman world to the crucifixion iconography throughout the Middle Ages.

A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At‐Risk Populations in Primary Care

PreyaJanubhai Patel, Fabrina Hossain, Leigh Ula Horsfall, Xuan Banh, Kelly Lee Hayward, Suzanne Williams, Tracey Johnson, Anne Bernard, Nigel Neil Brown, Guy Lampe, Lyndall Buck, Nivene Saad, Anthony William Russell, Patricia Casarolli Valery, Katharine Margaret Irvine, Andrew Donald Clouston, Katherine Anne Stuart, William Rosenberg, Elizabeth Ellen Powell – 6 August 2018 – Noninvasive serum biomarkers (nonalcoholic fatty liver disease fibrosis score [NFS], fibrosis 4 score [FIB‐4], or enhanced liver fibrosis [ELF] test) are recommended as first‐line tools to determine the risk of advanced

Liver Transplantation for Propionic Acidemia and Methylmalonic Acidemia: Perioperative Management and Clinical Outcomes

Kristen Critelli, Patrick McKiernan, Jerry Vockley, George Mazariegos, Robert H. Squires, Kyle Soltys, James E. Squires – 6 August 2018 – Propionic acidemia (PA) and methylmalonic acidemia (MMA) comprise the most common organic acidemias and account for profound morbidity in affected individuals. Although liver transplantation (LT) has emerged as a bulk enzyme‐replacement strategy to stabilize metabolically fragile patients, it is not a metabolic cure because patients remain at risk for disease‐related complications.

Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis–Inflammatory Bowel Disease

Brian K. Chung, Eva Kristine Klemsdal Henriksen, Kristin Kaasen Jørgensen, Tom H. Karlsen, Gideon M. Hirschfield, Evaggelia Liaskou – 6 August 2018 – B cells express an antigen‐specific B‐cell receptor (BCR) and may contribute to liver inflammation by recognizing shared antigens in the gut and liver.

L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis

Masatsugu Ohara, Koji Ogawa, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Kazuharu Suzuki, Akihisa Nakamura, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Shunsuke Ohnishi, Naoya Sakamoto – 6 August 2018 – Liver cirrhosis (LC) is a major cause of secondary sarcopenia. Sarcopenia makes the prognosis worse; thus, novel therapeutic options for sarcopenia in patients with LC are urgently required as they are currently limited.

Liver Transplantation Today: Where We Are Now and Where We Are Going

Adam S. Bodzin, Talia B. Baker – 6 August 2018 – Liver transplantation was made a reality through the bravery, innovation, and persistence of Dr. Thomas Starzl. His death in 2017, at the age of 90, makes us pause to consider how far the field has come since its inception by this remarkable pioneer. It also is an opportunity to evaluate the continued novel innovations which contribute to the growth and potential for liver transplantation in the future.

L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis

Masatsugu Ohara, Koji Ogawa, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Kazuharu Suzuki, Akihisa Nakamura, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Shunsuke Ohnishi, Naoya Sakamoto – 6 August 2018 – Liver cirrhosis (LC) is a major cause of secondary sarcopenia. Sarcopenia makes the prognosis worse; thus, novel therapeutic options for sarcopenia in patients with LC are urgently required as they are currently limited.

Subscribe to